Therefore, although further in vivo studies are still required to confirm the effects of A5, C1 and APO on GBM and non-tumorigenic cells, our data support a potential therapeutic application of A5 and C1 as new cytotoxic agents against GBM tumors. Here, AOPEP is linked to glioblastoma.